🚀 VC round data is live in beta, check it out!
Ajanta Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Ajanta Pharma and similar public comparables like Kanghong Pharmaceutical, Zelgen Biopharmaceuticals, Hikma Pharmaceuticals, Aspen Pharmacare and more.
Ajanta Pharma Overview
About Ajanta Pharma
Ajanta Pharma Ltd is a drug manufacturing company with a focus on specialty pharmaceutical products. The company maintains a presence while generating the vast majority of its revenue in India. The company aims to successfully select molecules and products for development while enhancing its research and development capabilities. The company works to develop formulations in different dosages such as tablets, creams, injectables, capsules, liquids, and lotion. The company's manufacturing plants are located in India.
Founded
1979
HQ
Employees
9.6K
Website
Sectors
Financials (LTM)
EV
$4B
Ajanta Pharma Financials
Ajanta Pharma reported last 12-month revenue of $581M and EBITDA of $157M.
In the same LTM period, Ajanta Pharma generated $451M in gross profit, $157M in EBITDA, and $114M in net income.
Revenue (LTM)
Ajanta Pharma P&L
In the most recent fiscal year, Ajanta Pharma reported revenue of $550M and EBITDA of $150M.
Ajanta Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $581M | XXX | $550M | XXX | XXX | XXX |
| Gross Profit | $451M | XXX | $375M | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $157M | XXX | $150M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBIT Margin | 25% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $114M | XXX | $109M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 20% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Ajanta Pharma Stock Performance
Ajanta Pharma has current market cap of $4B, and enterprise value of $4B.
Market Cap Evolution
Ajanta Pharma's stock price is $29.80.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4B | $4B | 2.1% | XXX | XXX | XXX | $0.87 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAjanta Pharma Valuation Multiples
Ajanta Pharma trades at 6.3x EV/Revenue multiple, and 23.2x EV/EBITDA.
EV / Revenue (LTM)
Ajanta Pharma Financial Valuation Multiples
As of April 11, 2026, Ajanta Pharma has market cap of $4B and EV of $4B.
Equity research analysts estimate Ajanta Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Ajanta Pharma has a P/E ratio of 32.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV (current) | $4B | XXX | $4B | XXX | XXX | XXX |
| EV/Revenue | 6.3x | XXX | 6.6x | XXX | XXX | XXX |
| EV/EBITDA | 23.2x | XXX | 24.4x | XXX | XXX | XXX |
| EV/EBIT | 25.5x | XXX | 27.3x | XXX | XXX | XXX |
| EV/Gross Profit | 8.1x | XXX | 9.7x | XXX | XXX | XXX |
| P/E | 32.6x | XXX | 34.2x | XXX | XXX | XXX |
| EV/FCF | 52.4x | XXX | 37.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ajanta Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Ajanta Pharma Margins & Growth Rates
Ajanta Pharma's revenue in the last 12 month grew by 13%.
Ajanta Pharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Ajanta Pharma's rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ajanta Pharma's rule of X is 62% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Ajanta Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 18% | XXX | 5% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Ajanta Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Kanghong Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Zelgen Biopharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Hikma Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Aspen Pharmacare | XXX | XXX | XXX | XXX | XXX | XXX |
| TransThera Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ajanta Pharma M&A Activity
Ajanta Pharma acquired XXX companies to date.
Last acquisition by Ajanta Pharma was on XXXXXXXX, XXXXX. Ajanta Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Ajanta Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAjanta Pharma Investment Activity
Ajanta Pharma invested in XXX companies to date.
Ajanta Pharma made its latest investment on XXXXXXXX, XXXXX. Ajanta Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Ajanta Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ajanta Pharma
| When was Ajanta Pharma founded? | Ajanta Pharma was founded in 1979. |
| Where is Ajanta Pharma headquartered? | Ajanta Pharma is headquartered in India. |
| How many employees does Ajanta Pharma have? | As of today, Ajanta Pharma has over 9K employees. |
| Is Ajanta Pharma publicly listed? | Yes, Ajanta Pharma is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Ajanta Pharma? | Ajanta Pharma trades under AJANTPHARM ticker. |
| When did Ajanta Pharma go public? | Ajanta Pharma went public in 2000. |
| Who are competitors of Ajanta Pharma? | Ajanta Pharma main competitors are Kanghong Pharmaceutical, Zelgen Biopharmaceuticals, Hikma Pharmaceuticals, Aspen Pharmacare. |
| What is the current market cap of Ajanta Pharma? | Ajanta Pharma's current market cap is $4B. |
| What is the current revenue of Ajanta Pharma? | Ajanta Pharma's last 12 months revenue is $581M. |
| What is the current revenue growth of Ajanta Pharma? | Ajanta Pharma revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Ajanta Pharma? | Current revenue multiple of Ajanta Pharma is 6.3x. |
| Is Ajanta Pharma profitable? | Yes, Ajanta Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Ajanta Pharma? | Ajanta Pharma's last 12 months EBITDA is $157M. |
| What is Ajanta Pharma's EBITDA margin? | Ajanta Pharma's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Ajanta Pharma? | Current EBITDA multiple of Ajanta Pharma is 23.2x. |
| What is the current FCF of Ajanta Pharma? | Ajanta Pharma's last 12 months FCF is $70M. |
| What is Ajanta Pharma's FCF margin? | Ajanta Pharma's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Ajanta Pharma? | Current FCF multiple of Ajanta Pharma is 52.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.